March 21, 2011 -- A Scottish pharmaceutical company is on the hunt for a clutch of world class scientists as it embarks on an aggressive growth drive. And as it recruits the top talent, it will also build up job numbers among sales and support staff.
Glasgow-based Drug Delivery International, established only at the start of 2011, is projecting first year turnover of at least £500,000 as it focuses on collaborative research, licensing agreements and breakthroughs into the lucrative Asian and Far Eastern markets.
Dr Carol Thomson, the chief operating officer who is in charge of the day-to-day running of the ambitious new company, said that DDi also intends to develop its own intellectual property and to take products through research and development to clinical trials under its own steam.
She said: “DDi has taken the first steps towards building a strong portfolio of growth potential products and we are actively seeking at least four scientists with first class pharmaceutical pedigrees to help us take the company to the next stage.”
For Dr Thomson, born in Glasgow the launch of DDi as a new contender in the intensely competitive international pharma sector is the latest stage in an already glittering career in management in the science sector.
Her first degree at Glasgow University was in genetics, an interest sparked by school biology lessons where she was taught the concept of Mendelian Inheritance.
The intellectually driven young geneticist worked her summers in prestigious labs up and down the country working spheres as diverse as genetics of parasites and cancer genetics as well as assisting the world-renowned Professor James Scott – founder and first Head of the Institute of Genetics and Genomics – with research into lipids in heart disease at the Hammersmith Hospital.
She did her Doctorate with Professor Sir Gordon Duff at the University of Sheffield, investigating genetic factors in rheumatoid arthritis and then followed these successes with intensive post-doctoral work on immuno-genetics.
However, she said, around this time she began to realise that she was ready for challenges other than focused lab work and joined Thomson Reuters, where she managed teams indexing and abstracting patents in the Pharmaceutical Patents Business Unit of the World Patents Index.
She said: “I was with this large organisation for seven years and I enormously enjoyed the combination of management and science – both disciplines which require focus, drive, intellectual rigour and integrity.”
Dr Thomson then joined the University of Strathclyde in a Business Development Manager role and subsequently as Research Policy Manager where she became involved in a Scottish Enterprise Proof of Concept fund project looking at the potential of chronotherapeutic – or time-delayed – drug delivery.
This led, with the involvement of respected pharmacists Professor Howard Stevens and Professor Alex Mullen, to the establishment of Drug Delivery International, which has already seized the chance to license three University of Strathclyde patents with the potential to create significant medical benefits across the world.
DDi – sister company of Bio-Images Research, which has just announced a major expansion into Asia – plans to further develop the technologies for licensing to pharmaceutical or generic companies and is actively seeking to become involved in collaborative research with interested parties.
The patents are in the area of controlled drug release and have been demonstrated in the therapeutic areas of cardiovascular disease, pain management and sleep. As a result of the licensing agreement, DDi has already entered into early stage discussions with a global pharmaceutical company to secure a collaborative research agreement with an option to license a controlled release drug formulation for pain control.
Dr Thomson said: “As we take on more scientists, employment opportunities in other areas of the company will also increase dramatically. Our growth plans are aggressive, focused and have considerable significance for the future health of the Scottish pharmaceutical sector.”
For more information, please contact Dr Carol Thomson of Drug Delivery International on 0141 552 8791 or c.thomson@dd-int.com, or Michael Crawford at Blueprint Media.
Issued by Michael Crawford at Blueprint Media, 0141 353 1515.
Date: 21 March 2011
Michael Crawford Account Manager Telephone: 0141 353 1515 Blueprint Media, 176 St. Vincent Street, Glasgow, G2 5SG
Visit our website on www.blueprintmedia.co.uk
You can now follow us on Twitter and connect with me on LinkedIn
